Tobramycin
Links shared publicly online about this topic
Gilead's Cayston Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study - Drugs.com MedNews
drugs.com — “Oct 21, 2010 - Gilead Sciences, Inc. (Nasdaq GILD) today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution)” View full resource at drugs.com
Most Recently Shared on October 21, 2010 at 8:16 pm By:
Drugs and Devices OW OW Health
Gilead's Cayston Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study: ... http://bit.ly/bsQH99 #drug
Infectious Disease Article | Lung Transplantation
mdlinx.com — “Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation” View full resource at mdlinx.com
Most Recently Shared on August 3, 2011 at 4:18 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation... http://bit.ly/qkDuZb #ID
Infectious Dis. Medical News about Pseudomonas aeruginosa
mdlinx.com — “Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients” View full resource at mdlinx.com
Most Recently Shared on July 2, 2010 at 12:06 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseud... http://bit.ly/93QYk7 #ID
Infectious Disease Article | Cystic Fibrosis
mdlinx.com — “Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial” View full resource at mdlinx.com
Most Recently Shared on November 9, 2010 at 10:22 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial: Pediatric Pul... http://bit.ly/9rfDWt #ID
Alcon Launches TobraDex(R) ST Suspension
medicalnewstoday.com — “Alcon (NYSE: ACL), the world's leading eye care company, announced the launch of its new combination anti-inflammatory/anti-infective product, TobraDex® ST suspension in the United States. Tob” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 6:05 pm By:
Alcon Launches TobraDex(R) ST Suspension http://mnt.to/3KhW #eyehealth
TOBI Podhaler for suppression of infection in cystic fibrosis | MIMS online
mims.co.uk — “The latest pharmaceutical, medical and drugs news on MIMS online” View full resource at mims.co.uk
Most Recently Shared on November 2, 2011 at 3:09 pm By:
Tobramycin now available as a dry powder inhalation formulation for pulmonary infections in cystic fibrosis: http://t.co/1y7M9pFd
Novel therapeutics demonstrate effective treatment for blepharitis
osnsupersite.com — “KOLOA, Hawaii " Both 1% azithromycin ophthalmic solution and tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension have been shown effective in tr” View full resource at osnsupersite.com
Most Recently Shared on January 22, 2010 at 4:46 pm By:
#OSNhe10 — Novel therapeutics demonstrate effective treatment for blepharitis: http://ow.ly/ZoWH
TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection
news-medical.net — “A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.” View full resource at news-medical.net
Most Recently Shared on October 22, 2010 at 7:35 am By:
TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection: A new analysis of data from more than ... http://bit.ly/cd3MiF
Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010
news-medical.net — “Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.” View full resource at news-medical.net
Most Recently Shared on June 19, 2010 at 7:58 am By:
Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010: Gile... http://bit.ly/cRz93x
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
